Record $59.4M sales but profit reverses at Champions Oncology (NASDAQ: CSBR)
Rhea-AI Filing Summary
Champions Oncology reported record fiscal 2026 oncology revenue of $59.4 million, up 4% from $56.9 million, driven by its core research services business despite the absence of approximately $4.5 million of prior-year data license revenue. Fourth-quarter revenue rose 12% to $13.8 million, and oncology services margin improved to 51% from 41% as costs of oncology revenue fell 6%.
Profitability weakened for the year. Champions posted a loss from operations of $1.1 million, versus income from operations of $4.6 million in fiscal 2025, and a GAAP net loss of $1.2 million versus prior-year net income of $4.7 million, reflecting higher outsourced radiopharmaceutical costs and increased R&D, sales and marketing, and G&A expenses. Adjusted EBITDA remained positive at $1.6 million, but declined from $7.1 million; in the fourth quarter, Adjusted EBITDA was $158,000 compared with a $1.2 million loss a year earlier.
Operating cash use in the fourth quarter was approximately $2.2 million, mainly from working-capital timing and lower deferred revenue. Champions ended April 30, 2026 with $4.9 million in cash and no debt while continuing to invest in radiopharmaceuticals, its data platform, and commercial organization.
Positive
- Record annual oncology revenue of $59.4 million and positive Adjusted EBITDA of $1.6 million show the core services business continued to grow and generate operating cash-style earnings even as the company invested heavily and lapped non-recurring data license revenue.
Negative
- GAAP net income swung from a $4.7 million profit to a $1.2 million loss, and Adjusted EBITDA fell from $7.1 million to $1.6 million, driven by higher outsourced radiopharmaceutical costs and rising operating expenses, indicating materially weaker profitability.
Filing Explained
The
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Annual oncology revenue: $59.4 million
Fourth-quarter oncology revenue: $13.8 million
GAAP net income (loss): ($1.2 million)
+5 more
8 metrics
Annual oncology revenue
$59.4 million
Fiscal year ended April 30, 2026; record level, up 4% from $56.9 million.
Fourth-quarter oncology revenue
$13.8 million
Three months ended April 30, 2026; up from $12.4 million, a 12% increase.
GAAP net income (loss)
($1.2 million)
Fiscal year 2026 net loss versus $4.7 million net income in fiscal 2025.
Adjusted EBITDA
$1.6 million
Fiscal year 2026, compared with $7.1 million in the prior fiscal year.
Q4 Adjusted EBITDA
$158,000
Three months ended April 30, 2026; improved from a $1.2 million loss a year earlier.
Oncology services margin (Q4)
51%
Fourth quarter of fiscal 2026, up from 41% in the prior-year quarter.
Cash balance
$4.9 million
Cash position at April 30, 2026; the company reported no debt.
Cost of oncology revenue
$30.9 million
Fiscal year 2026, an increase of $2.5 million or 8.8% from fiscal 2025.
Key Terms
Adjusted EBITDA, Non-GAAP financial measures, Oncology services margin, radiopharmaceutical, +2 more
6 terms
Adjusted EBITDA financial
"Adjusted EBITDA income, which is defined as net income excluding stock-based compensation"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Non-GAAP financial measures financial
"This press release contains “Non-GAAP financial measures,” which are measures that either exclude or include"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Oncology services margin financial
"Combined with higher revenue, these factors generated improved operating leverage and increased oncology services margin to 51%"
Oncology services margin is the percentage of revenue a business keeps after paying the direct costs of providing cancer care — such as drugs, clinical staff, infusion centers and related supplies. For investors it shows how efficiently a company turns cancer-treatment revenue into profit, similar to how a baker’s margin reflects the difference between the price of a cake and the cost of ingredients and labor; higher margins imply stronger pricing, cost control or reimbursement terms.
radiopharmaceutical technical
"including expanding our radiopharmaceutical platform, strengthening our data strategy"
A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.
patient-derived xenograft (PDX) medical
"largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary"
A patient-derived xenograft (PDX) is a laboratory model created by implanting a small piece of a human tumor into an immune-compromised animal, most often a mouse, so the cancer can grow in a living system. Investors care because PDX models are used to test whether experimental drugs shrink real human tumors before expensive clinical trials, serving like a dress rehearsal that can help predict success, reduce risk, and guide which drug candidates move forward.
deferred revenue financial
"higher accounts receivable due to the timing of customer collections and a reduction in deferred revenue"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
Earnings Snapshot
Oncology revenue (fiscal year): $59.4 million
Fiscal year and fourth quarter ended April 30, 2026
Oncology revenue (fiscal year)
$59.4 million
Increased 4% from $56.9 million in fiscal 2025.
GAAP net income (loss, fiscal year)
($1.2 million)
Compared with $4.7 million net income in fiscal 2025, reflecting higher costs and no repeat of data license revenue.
Adjusted EBITDA (fiscal year)
$1.6 million
Down from $7.1 million in fiscal 2025 but positive in all four quarters of fiscal 2026.
Oncology revenue (Q4)
$13.8 million
Rose from $12.4 million in the prior-year quarter, a 12% increase.
Oncology services margin (Q4)
51%
Improved from 41% in the fourth quarter of fiscal 2025 as costs declined and revenue grew.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Champions Oncology (CSBR) perform financially in fiscal year 2026?
Champions Oncology generated $59.4 million in oncology revenue, up 4%, but reported a GAAP net loss of $1.2 million. Adjusted EBITDA remained positive at $1.6 million, down from $7.1 million in fiscal 2025 as costs and investments increased.
What drove Champions Oncology (CSBR) revenue growth in FY 2026?
Revenue rose 4% to $59.4 million, led by continued strength in the core research services business. This growth more than offset the non-repeat of approximately $4.5 million in data license revenue recognized in fiscal 2025 that did not recur in fiscal 2026.
Why did Champions Oncology (CSBR) profitability decline compared with fiscal 2025?
Profitability declined because fiscal 2026 lacked about $4.5 million of prior-year data license revenue and saw higher outsourced radiopharmaceutical costs and increased R&D, sales and marketing, and G&A spending, resulting in a $1.1 million operating loss versus prior-year operating income.
What were Champions Oncology (CSBR) fourth quarter 2026 results?
In Q4 2026, Champions Oncology posted oncology revenue of $13.8 million, up 12%, with oncology services margin improving to 51%. The company recorded a $522,000 loss from operations, but delivered positive Adjusted EBITDA of $158,000 compared with a $1.2 million loss a year earlier.
What is Champions Oncology (CSBR) cash and debt position as of April 30, 2026?
As of April 30, 2026, Champions Oncology held $4.9 million in cash and reported no debt. Fourth-quarter operating activities used approximately $2.2 million of cash, mainly due to higher accounts receivable and reduced deferred revenue from timing of customer collections.
How does Champions Oncology (CSBR) define Adjusted EBITDA and why is it important?
Adjusted EBITDA excludes stock-based compensation, depreciation and amortization, losses on equipment disposal, other income, and taxes from net income. Management uses it to evaluate ongoing operations and compare performance across periods, viewing it as a key non-GAAP measure alongside oncology services margin.
What cost trends affected Champions Oncology (CSBR) in fiscal 2026?
Cost of oncology revenue rose to $30.9 million, up 8.8%, largely from outsourced radiopharmacology services ahead of transitioning activities in-house. R&D, sales and marketing, and G&A expenses also increased, reflecting investment in the data platform, commercial organization, and supporting infrastructure.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 27, 2026
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of Incorporation) | Identification No.) | |||||||||||||
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201 ) 808-8400
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Exchange Act
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Common Stock, par value $0.001 per share | CSBR | The Nasdaq Stock Market LLC | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
INFORMATION TO BE INCLUDED IN THE REPORT
| Item 2.02. | Results of Operations and Financial Condition. | |||||||
On July 27, 2026, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
The following exhibit is filed herewith:
Exhibit No.
| 99.1 | Press Release dated July 27, 2026 | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS ONCOLOGY, INC. | |||||||||||
| (Registrant) | |||||||||||
Date: July 27, 2026 | By: | /s/ Robert Brainin | |||||||||
| Robert Brainin | |||||||||||
| Chief Executive Officer | |||||||||||
Exhibit 99.1
NEWSOne University Plaza, Suite 307 Hackensack, NJ 07601
Champions Oncology Reports Record Annual Revenue of $59 Million
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA
Hackensack, NJ – July 27, 2026 – Champions Oncology, Inc. (Nasdaq: CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026.
Fourth Quarter and Other Financial Highlights:
•Record annual revenue of $59.4 million
•Fourth quarter revenue of $13.8 million
•Fourth quarter oncology services margin of 51%
•Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year
•Adjusted EBITDA income all four quarters in FY 2026
•Continued investment in radiopharmaceuticals, the data platform and commercial organization
Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth. Our core research services business performed well as we advanced several strategic initiatives, including expanding our radiopharmaceutical platform, strengthening our data strategy, making meaningful progress toward the commercial application of Corellia's technology, and growing our commercial organization. We believe these investments strengthen our competitive position and expand our opportunities for long-term growth, and we remain focused on building on this momentum."
David Miller, CFO of Champions added, "Our financial results for fiscal 2026 reflect the strength of our core research services business. We delivered record annual revenue despite the absence of the prior year's significant data licensing transaction and generated positive Adjusted EBITDA in each quarter of the fiscal year, reflecting our disciplined approach to managing our cost structure while continuing to invest in our strategic initiatives. We remain focused on allocating capital prudently to support the Company's long-term growth objectives."
Fourth Quarter Financial Results
Total oncology revenue for the fourth quarter of fiscal 2026 was $13.8 million, compared to $12.4 million for the same period last year, an increase of 12%. Total costs and operating expenses for both the fourth quarter of fiscal 2026 and 2025 were $14.4 million.
Exhibit 99.1
For the fourth quarter of fiscal 2026, Champions reported a loss from operations of $522,000, which includes $357,000 in stock-based compensation, $322,000 in depreciation and amortization, and a $1,000 charge on the disposal of lab equipment, compared to a loss from operations of $2.0 million, inclusive of $131,000 in stock-based compensation, $394,000 in depreciation and amortization, and a $293,000 charge on the disposal of lab equipment in the fourth quarter of fiscal 2025. Adjusted EBITDA income, which is defined as net income excluding stock-based compensation, depreciation and amortization expenses, a loss on the sale and / or disposal of lab equipment, other income, and taxes, was $158,000 for the quarter, compared to an adjusted EBITDA loss of $1.2 million in the prior year period.
Cost of oncology revenue was $6.8 million for three months ended April 30, 2026, as compared to $7.3 million for the three months ended April 30, 2025, a decrease of $462,000 or 6%. The reduction reflected continued cost discipline, lower outsourced research services expenses, including the continued transition of certain radiopharmaceutical activities in-house, and lower compensation expense. Combined with higher revenue, these factors generated improved operating leverage and increased oncology services margin to 51% from 41% in the prior-year period. Oncology services margin and profit are defined below in our Non-GAAP financial information discussion.
Research and development, sales and marketing, and general and administrative expenses remained well controlled during the quarter as the Company continued to invest in strategic growth initiatives. Research and development expense was $2.1 million for the three months ended April 30, 2026, compared to $2.0 million in the prior-year period. Sales and marketing expense increased to $2.8 million from $2.3 million in the prior-year period, primarily reflecting investments to expand the Company's commercial capabilities across both its core research services business and data platform. General and administrative expense increased modestly to $2.6 million from $2.5 million, primarily reflecting higher compensation, including stock-based compensation, and information technology investments supporting the continued growth of the business.
Net cash used in operating activities for the quarter was approximately $2.2 million, driven primarily by working capital timing rather than underlying operating performance. The decrease reflected higher accounts receivable due to the timing of customer collections and a reduction in deferred revenue. Net cash used in investing activities for the quarter was approximately $44,000 for the purchase of lab and computer equipment. Net cash used in financing activities for the quarter was $19,000 resulting from financing lease payments. The Company ended the quarter with a cash position of $4.9 million and no debt.
Year-to-Date Financial Results
Total oncology revenue for fiscal year 2026 was $59.4 million, an increase of 4%, compared to $56.9 million for fiscal year 2025. The increase was driven by continued strength in the Company's core research services business, which more than offset the absence of approximately $4.5 million of data license revenue recognized in the prior fiscal year that did not recur in fiscal 2026. Total operating expenses increased $8.2 million to $60.6 million from $52.4 million in the prior year, primarily reflecting approximately $3.0 million of higher outsourced radiopharmaceutical costs incurred while supporting customer programs prior to transitioning certain activities in-house, as well as continued investment in the Company's commercial organization and data platform.
For the twelve months ended April 30, 2026, Champions reported a loss from operations of $1.1 million, which includes $1.2 million in stock-based compensation, $1.4 million in depreciation and amortization, and a $111,000 loss on the disposal of laboratory equipment, compared to
Exhibit 99.1
income from operations of $4.6 million in the prior year, which included $654,000 in stock-based compensation, $1.6 million in depreciation and amortization, and a $293,000 loss on disposal of laboratory equipment. The year-over-year comparison reflects the absence of the prior year's non-recurring data license revenue, together with the Company's continued investments in its commercial organization, data platform, and radiopharmaceutical capabilities. Adjusted EBITDA was $1.6 million for fiscal year 2026, compared to $7.1 million for the prior fiscal year.
Cost of oncology revenue was $30.9 million for the twelve months ended April 30, 2026, an increase of $2.5 million or 8.8%, compared to $28.4 million for the twelve months ended April 30, 2025. The increase was primarily due to outsourced laboratory services incurred to perform radiopharmacology studies while the Company continued to build its internal radiopharmacology capabilities. Oncology services margin was 48% for the twelve months ended April 30, 2026, compared to 50% for the prior year. The decrease in margin primarily reflected these temporary outsourced laboratory costs.
Research and development expense was $9.1 million for fiscal year 2026, an increase of $2.3 million, or 33%, compared to $6.8 million for the prior year. The increase primarily reflected continued investment in the Company's data platform, including higher sequencing and laboratory costs. Sales and marketing expense was $9.3 million for fiscal year 2026, an increase of $1.8 million, or 23%, compared to $7.5 million for fiscal year 2025. The increase was primarily due to the continued expansion of the Company's sales teams supporting both its core research services and data offerings. General and administrative expense was $11.2 million for fiscal year 2026, an increase of $1.8 million, or 19%, compared to $9.3 million for fiscal year 2025. The increase primarily reflected higher compensation, including stock-based compensation, and increased information technology investments to support the continued growth of the business.
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. ET (1:30 p.m. PT) to discuss its fourth quarter financial results. To participate in the call, please call 888-506-0062 (domestic) or 973-528-0011 (international) ten minutes ahead of the call and enter the access code 347142. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 54320, or by accessing the investors section of the company's website within 72 hours.
Full details of the Company’s financial results will be available on later today and no later than Wednesday July 29, 2026 in the Company’s Form 10-K at https://www.championsoncology.com.
* Non-GAAP Financial Information
This press release contains “Non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”).
A further explanation and reconciliation of these Non-GAAP financial measures is included below and in the financial tables in this release.
Exhibit 99.1
The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities (when applicable) as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.
Adjusted EBITDA
Adjusted EBITDA represents net income (loss), or net income (loss) from operations, excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)
Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Oncology Services Profit and Oncology Services Margin
Oncology Services Profit is a Non-GAAP measure calculated as oncology revenue less cost of oncology revenue. Cost of oncology revenue is comprised primarily of expenses for mice, laboratory supplies, compensation, and outsourced lab services. Oncology Services margin is a Non-GAAP measure calculated as oncology services profit divided by oncology revenue.
Management believes that Oncology Services Profit and Oncology Services margin are metrics which provide a clear view of direct profitability before research and development, sales and marketing, and administrative expenses are factored into our results. Management monitors these metrics closely as an indicator of pricing strategy effectiveness and resource utilization. These non-GAAP measures should not be considered in isolation or as a substitute for GAAP measures such as operating income (loss) and net income (loss). A reconciliation to the most directly comparable GAAP measure is provided in the accompanying tables.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality
Exhibit 99.1
data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2026 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (Unaudited)
| Three Months Ended April 30, | Twelve Months Ended April 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net income (loss) - GAAP | $ | (667) | $ | (1,834) | $ | (1,175) | $ | 4,701 | |||||||||||||||
| Less: | |||||||||||||||||||||||
| Stock-based compensation | $ | 357 | $ | 131 | $ | 1,237 | $ | 654 | |||||||||||||||
| Depreciation and amortization | $ | 322 | $ | 394 | $ | 1,377 | $ | 1,640 | |||||||||||||||
| Loss on equipment disposal | $ | 1 | $ | 293 | $ | 111 | $ | 293 | |||||||||||||||
| Other income, net | $ | (27) | $ | (42) | $ | (211) | $ | (73) | |||||||||||||||
| Provision (benefit) for taxes | $ | 172 | $ | (130) | $ | 246 | $ | (75) | |||||||||||||||
| Adjusted EBITDA - Non-GAAP | $ | 158 | $ | (1,188) | $ | 1,585 | $ | 7,140 | |||||||||||||||
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
| Three Months Ended April 30, | Twelve Months Ended April 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| EPS – GAAP, basic | $ | (0.05) | $ | (0.13) | $ | (0.08) | $ | 0.34 | |||||||||||||||
| Less: | |||||||||||||||||||||||
| Effect of stock-based compensation on EPS | $ | 0.03 | $ | 0.01 | $ | 0.09 | $ | 0.05 | |||||||||||||||
| Effect of depreciation and amortization on EPS | $ | 0.02 | $ | 0.03 | $ | 0.10 | $ | 0.12 | |||||||||||||||
| Effect of loss on equipment disposal on EPS | $ | — | $ | 0.02 | $ | 0.01 | $ | 0.02 | |||||||||||||||
| Effect of other income, net on EPS | $ | — | $ | — | $ | (0.02) | $ | (0.01) | |||||||||||||||
| Effect of provision (benefit) for taxes on EPS | $ | 0.01 | $ | (0.01) | $ | 0.02 | $ | (0.01) | |||||||||||||||
| Adjusted EPS - basic, Non-GAAP | $ | 0.01 | $ | (0.08) | $ | 0.12 | $ | 0.51 | |||||||||||||||
| Three Months Ended April 30, | Twelve Months Ended April 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| EPS – GAAP, diluted | $ | (0.05) | $ | (0.13) | $ | (0.08) | $ | 0.33 | |||||||||||||||
| Less: | |||||||||||||||||||||||
| Effect of stock-based compensation on EPS | $ | 0.03 | $ | 0.01 | $ | 0.09 | $ | 0.05 | |||||||||||||||
| Effect of depreciation and amortization on EPS | $ | 0.02 | $ | 0.03 | $ | 0.10 | $ | 0.11 | |||||||||||||||
| Effect of loss on equipment disposal on EPS | $ | — | $ | 0.02 | $ | 0.01 | $ | 0.02 | |||||||||||||||
| Effect of other income, net on EPS | $ | — | $ | — | $ | (0.02) | $ | (0.01) | |||||||||||||||
| Effect of provision (benefit) for taxes on EPS | $ | 0.01 | $ | (0.01) | $ | 0.02 | $ | (0.01) | |||||||||||||||
| Adjusted EPS - diluted, Non-GAAP | $ | 0.01 | $ | (0.08) | $ | 0.12 | $ | 0.49 | |||||||||||||||
Condensed Consolidated Statements of Operations (Unaudited)
| Three Months Ended April 30, | Twelve Months Ended April 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Oncology revenue | $ | 13,835 | $ | 12,355 | $ | 59,425 | $ | 56,944 | |||||||||||||||
| Costs and operating expenses: | |||||||||||||||||||||||
| Cost of oncology revenue | 6,809 | 7,271 | 30,900 | 28,389 | |||||||||||||||||||
| Research and development | 2,115 | 1,963 | 9,084 | 6,825 | |||||||||||||||||||
| Sales and marketing | 2,798 | 2,309 | 9,318 | 7,545 | |||||||||||||||||||
| General and administrative | 2,634 | 2,525 | 11,152 | 9,339 | |||||||||||||||||||
| Loss on disposal of equipment | 1 | 293 | 111 | 293 | |||||||||||||||||||
| Income (loss) from operations | $ | (522) | $ | (2,006) | $ | (1,140) | $ | 4,553 | |||||||||||||||
| Other income, net | 27 | 42 | 211 | 73 | |||||||||||||||||||
| Net income (loss) before provision (benefit) for income taxes | $ | (495) | $ | (1,964) | $ | (929) | $ | 4,626 | |||||||||||||||
| Provision (benefit) for income taxes | 172 | (130) | 246 | (75) | |||||||||||||||||||
| Net income (loss) | $ | (667) | $ | (1,834) | $ | (1,175) | $ | 4,701 | |||||||||||||||
| Net income (loss) per common share outstanding | |||||||||||||||||||||||
| basic | $ | (0.05) | $ | (0.13) | $ | (0.08) | $ | 0.34 | |||||||||||||||
| and diluted | $ | (0.05) | $ | (0.13) | $ | (0.08) | $ | 0.33 | |||||||||||||||
| Weighted average common shares outstanding | |||||||||||||||||||||||
| basic | 13,886,819 | 13,753,575 | 13,832,385 | 13,659,786 | |||||||||||||||||||
| and diluted | 13,886,819 | 13,753,575 | 13,832,385 | 14,266,781 | |||||||||||||||||||
Condensed Consolidated Balance Sheets as of
| April 30, 2026 | April 30, 2025 | ||||||||||
| Cash | $ | 4,872 | $ | 9,785 | |||||||
| Accounts receivable | 13,178 | 11,204 | |||||||||
| Prepaid expenses and other current assets | 1,169 | 1,369 | |||||||||
| Total current assets | 19,219 | 22,358 | |||||||||
| Property and equipment, net | $ | 3,526 | $ | 4,375 | |||||||
| Operating lease right-of-use assets, net | 3,697 | 5,080 | |||||||||
| Other long term assets | 212 | 196 | |||||||||
| Goodwill | 335 | 335 | |||||||||
| Total assets | $ | 26,989 | $ | 32,344 | |||||||
| Accounts payable | 6,903 | 4,248 | |||||||||
| Accrued liabilities | 2,592 | 2,556 | |||||||||
| Current portion of operating lease liabilities | 1,520 | 1,471 | |||||||||
| Other current liability | 79 | 135 | |||||||||
| Deferred revenue | 8,828 | 15,443 | |||||||||
| Total current liabilities | 19,922 | 23,853 | |||||||||
| Non-current portion operating lease liabilities | 2,992 | 4,634 | |||||||||
| Other non-current liabilities | 7 | 85 | |||||||||
| Total Liabilities | 22,921 | 28,572 | |||||||||
| Total stockholders’ equity attributable to Champions Oncology, Inc. | 3,939 | 3,772 | |||||||||
| Noncontrolling interest | 129 | — | |||||||||
| Total stockholders' equity | 4,068 | 3,772 | |||||||||
| Total liabilities and stockholders’ equity | $ | 26,989 | $ | 32,344 | |||||||
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Twelve Months Ended April 30, | ||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||
| Cash flows from operating activities: | ||||||||||||||||||||
| Net income (loss) | $ | (1,175) | $ | 4,701 | ||||||||||||||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||||||||||||||
| Stock-based compensation expense | 1,237 | 654 | ||||||||||||||||||
| Depreciation and amortization expense | 1,377 | 1,640 | ||||||||||||||||||
| Operating lease right of use assets | 1,383 | 1,172 | ||||||||||||||||||
| Loss on sale and disposal of equipment | 111 | 293 | ||||||||||||||||||
| Allowance and estimated credit losses | 28 | (272) | ||||||||||||||||||
| Decrease in uncertain tax position | — | (181) | ||||||||||||||||||
| Gain on termination of operating lease | (9) | — | ||||||||||||||||||
| Changes in operating assets and liabilities | (7,424) | (621) | ||||||||||||||||||
| Net cash (used in) provided by operating activities | (4,472) | 7,386 | ||||||||||||||||||
| Cash flows from investing activities: | ||||||||||||||||||||
| Purchases of property and equipment | (564) | (389) | ||||||||||||||||||
| Proceeds from sale of equipment | 24 | — | ||||||||||||||||||
| Net cash used in investing activities | (540) | (389) | ||||||||||||||||||
| Cash flows from financing activities: | ||||||||||||||||||||
| Finance lease payments | (135) | (150) | ||||||||||||||||||
| Proceeds from exercise of options | 234 | 320 | ||||||||||||||||||
| Net cash provided by financing activities | 99 | 170 | ||||||||||||||||||
| Increase (decrease) in cash | (4,913) | 7,167 | ||||||||||||||||||
| Cash, beginning of period | 9,785 | 2,618 | ||||||||||||||||||
| Cash, end of period | $ | 4,872 | $ | 9,785 | ||||||||||||||||
| Non-cash investing activities: | ||||||||||||||||||||
| Equipment purchased in accounts payable | 98 | 197 | ||||||||||||||||||